Given the genetic heterogeneity and aberrations in breast cancer, the clinically generalized standard for subtype distinction is based on the expression of estrogen receptor α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2). This evidence concerns the gene ESR1 and breast cancer.